SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 706.40+0.3%9:39 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Felix B who wrote (2332)3/2/2018 2:33:04 AM
From: Miljenko Zuanic  Read Replies (1) of 3559
 
Why?
There was no harm to Eylea US sale for jan-feb period, and there was not at all any problem for ex-US.
Bloomberg article was PAID/ORCESTERED by someone who wanted to spread fear about Eylea future, after it dominate in US and ex-US 4Q. And will continue to dominate in 2018/19....unless there is restriction in CMS part B program.
I was surprise that there was not even more positive trend, regardless sell off in general market. Fear from CVOT uncertainty is present.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News